Pharmacovigilance – Products

Encouraging preliminary data from the ongoing DIPG clinical study to be presented at the 2023 Society for Neuro-Oncology Annual Meeting in Vancouver.

Glox Therapeutics, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.

Armis Biopharma, Inc. announced that the company received a $20.3 million contract from the Defense Threat Reduction Agency (DTRA) to develop its proprietary Veriox® DECON chemical warfare agent (CWA) decontamination product.

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.

A team of scientists have developed a protocol for the fabrication of a 3D microfluidic neuromuscular platform that can be used to model Motor Neuron Diseases (MND’s).

Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat cancers.

The Agilent Seahorse XF MitoTox assay kit allows for the direct functional measurements of mitochondrial oxygen consumption rates (OCR) and identification of drug-induced mitochondrial toxicity in drug safety evaluation studies

Form Bio, announced capabilities for cell and gene therapy companies to rapidly model billions of potential construct candidates.

Kuano, announced the close of its £1.8M seed funding round. The investment will facilitate further validation of Kuano’s quantum simulation platform for the design of more effective drug candidates targeting enzymes.

Novartis presents new patient-reported outcomes (PRO) data from the Phase III NATALEE trial at the European Society for Medical Oncology (ESMO) Virtual Plenary.